Louis Farge

CEO at Epynext Therapeutics
  • Claim this Profile
Contact Information
Location
Greater Paris Metropolitan Region, FR

Topline Score

Bio

Generated by
Topline AI

5.0

/5.0
/ Based on 2 ratings
  • (2)
  • (0)
  • (0)
  • (0)
  • (0)

Filter reviews by:

You need to have a working account to view this content. Click here to join now
Iain McGill

Louis is an excellent strategic and operational manager who worked for me over a broad geographic region. He is a strong team leader and builds excellent partnerships with senior customers. I would recommend Louis for a broad P&L managment position.

Luc Jacobs

I recruited Louis into Wyeth Pharmaceuticals to create and execute an e-business strategy for the Europe/Middle-East/Africa region. Louis fully delivered on my and the company's expectations. He quickly identified the key areas where the use of the internet could bring strategic value to the business at a regional level, but especially at the affiliate level. He was then instrumental in hiring a quality regional team which worked very collaboratively with the affiliates in order to generate high quality and customer oriented websites at excellent costs. He was always looking at best practices and economies of scale. I very much enjoyed working with Louis: his strategic thinking as well as his hands-on and collaborative style in the execution were keys to his success. Louis also possesses excellent project management skills to deliver complex project on time and within budget.

0

/5.0
/ Based on 0 ratings
  • (0)
  • (0)
  • (0)
  • (0)
  • (0)

Filter reviews by:

No reviews to display There are currently no reviews available.
You need to have a working account to view this content. Click here to join now

Experience

    • France
    • Biotechnology Research
    • 1 - 100 Employee
    • CEO
      • Nov 2020 - Present

      Epynext Therapeutics develop a new generation of monoclonal antibodies targeting mutli-resistant bacterias. Epynext Therapeutics develop a new generation of monoclonal antibodies targeting mutli-resistant bacterias.

    • France
    • Medical Equipment Manufacturing
    • Founder and Partner
      • Apr 2011 - Jun 2023

      • A web-based platform to facilitate patients journeys and therapeutic education in severe chronic diseases. • First digital cohort of nephrology patients in France, 12 major hospital units involved. • Secured funding from the French Ministry of Health. • Relationships with private investors, winner of several start-ups awards. • A web-based platform to facilitate patients journeys and therapeutic education in severe chronic diseases. • First digital cohort of nephrology patients in France, 12 major hospital units involved. • Secured funding from the French Ministry of Health. • Relationships with private investors, winner of several start-ups awards.

    • Owner
      • Jan 2017 - Nov 2022

      Consulting and transformation projects lead -For an early-stage biotech: business planning and development, communication and dossier preparation for investors and public funding bank. -For an immuno-oncology biotech (Euronext): scientific and economic intelligence, marketing strategy, investors & industrial partners communication. - For a big pharmaceutical: strategic planning of a major launch in diabetes. -Various 3 months to 3 years projects for big pharmaceuticals: business planning, business excellence, international project management. -Mentor and expert for EIT Health and MIT Hacking Medicine networks. Show less

    • France
    • Real Estate
    • Director Transplantation EMEA
      • Feb 2009 - Apr 2011

      Sales of 150M$, 75 people.Coordinating brand teams across the region.Regional KOLs management.Strategic recommendation following Pfizer's acquisition.

    • Transplantation Business Unit Director Belgium-France-Netherlands
      • Feb 2006 - Jan 2009

      Sales of 20M$, 15 peopleSetting up of a new operational organization, definition of the new activity and performance monitoring tools.Member of the Global Transplant Leadership Team and of the European brand management team.

    • e-Business Director EMEA
      • Mar 2001 - Feb 2006

      Reporting into the EMEA President and the EMEA Operational Committee.Definition and implementation of key strategic projects across European affiliates: eMarketing, eLearning and intranet.More than 50 sites and applications implemented across Europe including DTC web sites.

    • United States
    • Insurance
    • 1 - 100 Employee
    • Manager
      • Jan 1999 - Mar 2001

      Management of International assignments at board level. Conception, presentation and successful sale of proposals to GlaxoWellcome, Jefferson Smurfit Group, MSD, Orion Pharma, Renault-Nissan. Management of International assignments at board level. Conception, presentation and successful sale of proposals to GlaxoWellcome, Jefferson Smurfit Group, MSD, Orion Pharma, Renault-Nissan.

    • Hungary
    • Area sales manager
      • Jul 1996 - Dec 1998

      Sales manager, north of France, 150 reps.First area in sales, growth and market share in 1998.

    • District manager
      • Jan 1994 - Jul 1996

      District manager, France, 10 reps.Fastest growing district in 1994 and 1995.

    • International product manager
      • 1992 - 1993

      International launch of a new ACE inhibitor, highest promotional budget of the company at that time. International launch of a new ACE inhibitor, highest promotional budget of the company at that time.

    • Marketing Manager
      • 1991 - 1992

      Management of a marketing team in the areas of arthritis, analgesics, rheumatoid arthritis and osteoporosis.

    • Product Manager
      • 1986 - 1991

Education

  • University of Pennsylvania - The Wharton School
    Global Positioning Seminar
    2005 - 2005
  • IAE FRANCE - Écoles Universitaires de Management
    Master’s Degree
    1985 - 1986
  • Paris-Sud University (Paris XI)
    Maîtrise / Master, Biochemistry
    1982 - 1984
  • Lycée Lakanal
    Maths sup / Maths spé biologie
    1979 - 1982

Community

You need to have a working account to view this content. Click here to join now